BMS Acquisition Strategy Heats Up With Kosan Buy
Executive Summary
Bristol-Myers Squibb will jump full throttle into the race to bring to market a new class of oncology medicines, heat shock protein 90 inhibitors, after acquiring Kosan Biosciences
You may also be interested in...
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012
Bristol Readies Saxagliptin Launch In Anticipation Of FDA Approval
Bristol-Myers Squibb expects its next launch, diabetes drug Onglyza, along with its expanding string of "pearls" - partnership deals - will place the firm in a superior position to offset generic losses in 2012
Bristol Reports Strong 2008 Earnings But Sharp Patent Cliffs Loom
Analysts question whether firm’s “string of pearls” growth strategy can offset patent hit.